close
close

Decoding Moderna’s Options Business: What’s the Bigger Picture?

Posted on by darion

Whales with a lot of money to spend have taken a clearly bearish stance Modern.

Analyzing the options history for Moderna (NASDAQ:MRNA) we discovered 8 transactions.

If we take into account the specifics of each transaction, it can be accurately stated that 25% of investors opened transactions with growth expectations and 75% with decline expectations.

Of the total transactions observed, 6 were sell transactions with a total value of $218,807 and 2 were buy transactions with a total value of $70,833.

Expected price movements

Based on trading activity, significant investors expected Moderna’s share price to be between $110 and $150 over the past three months.

Volume and Open Interest Trends

Volume and open interest research provides key insights into stock analysis. This information is key to assessing the liquidity and interest levels of Moderna options at specific strike prices. Below is a snapshot of the trends in volume and open interest for call and put options in significant Moderna trades between strike prices of $110.0 and $150.0 over the past month.

Moderna Options Volume and Open Interest Over the Last 30 Days

Call Option Chart

Biggest options noticed:

Symbol PUT/CALL Type of trade Sentiment The term of validity Ask Offer Price Execution price Total Trade Price Open interest volume
MRNA PLACE TRADE BULLISH 08.02.24 $6.85 6.5 dollars 6.5 dollars 120.00 PLN $65.0k 223 0
MRNA CALL SWEEP BEARISH 26.07.24 5.1 $4.85 $4.85 118.00 PLN $37.8k 52 16
MRNA PLACE TRADE BEARISH 20.06.25 25.00 PLN 24.00 PLN 25.00 PLN $125.00 37.5 thousand dollars 115 0
MRNA PLACE TRADE BEARISH 21.03.25 22.5 dollars 22.3 PLN 22.5 dollars $125.00 33.7 thousand dollars 80 0
MRNA CALL SWEEP BULLISH 16.08.24 8.3 PLN 8.15 PLN 8.25 PLN 120.00 PLN $32.9k 3.1 thousand 39

About Moderna

Moderna is a commercial biotechnology company that was founded in 2010 and had its initial public offering in December 2018. The company’s mRNA technology was rapidly validated for a COVID-19 vaccine, which was approved in the United States in December 2020. Moderna had 39 mRNA candidates in clinical development as of mid-2023. The programs span a broad range of therapeutic areas, including infectious diseases, oncology, cardiovascular disease, and rare genetic diseases.

After a thorough review of the options trading surrounding Moderna, we move on to a more in-depth examination of the company. This includes an assessment of its current market status and performance.

Moderna’s Current Market Status

  • On a trading volume of 400,293, MRNA price fell by -1.54% to $119.45.
  • Current RSI values ​​indicate that the stock may be approaching oversold levels.
  • The next earnings report is due in 13 days.

Options trading comes with greater risk and potential reward. Smart traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay up to date on the latest Moderna options trades with real-time alerts from Benzinga Pro.